Verve Therapeutics (VERV) News Today $6.14 +0.04 (+0.66%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period How Advanced Drug Delivery is Revolutionizing Global Healthcare in 2025January 17 at 10:33 PM | baystreet.caVerve Therapeutics (NASDAQ:VERV) Trading 8.6% Higher - Time to Buy?Verve Therapeutics (NASDAQ:VERV) Trading Up 8.6% - Time to Buy?January 16 at 5:08 PM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLCBarclays PLC grew its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 139.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 222,919 shares of the company's stock afJanuary 15, 2025 | marketbeat.comVerve Therapeutics announces anticipated 2025 milestonesJanuary 13, 2025 | markets.businessinsider.comVerve Therapeutics sees cash runway into mid-2027January 13, 2025 | markets.businessinsider.comVerve Therapeutics Announces Pipeline Progress and Anticipated 2025 MilestonesJanuary 13, 2025 | finance.yahoo.comVerve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | finance.yahoo.comKuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law FirmJanuary 7, 2025 | markets.businessinsider.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comVerve Therapeutics (NASDAQ:VERV) Trading 6.2% Higher - What's Next?Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.2% - Still a Buy?January 3, 2025 | marketbeat.comBarclays PLC Purchases 129,944 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)Barclays PLC grew its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 139.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 222,919 shares of the company's stock after purchasingDecember 31, 2024 | marketbeat.comWhy Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?December 30, 2024 | msn.comVerve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | msn.comVerve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.comVerve Therapeutics (NASDAQ:VERV) Trading Down 5.9% - Should You Sell?Verve Therapeutics (NASDAQ:VERV) Trading Down 5.9% - Should You Sell?December 27, 2024 | marketbeat.comState Street Corp Boosts Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)State Street Corp grew its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 27.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,253,217 shares of the company's stock after purchDecember 24, 2024 | marketbeat.comVerve Therapeutics Slides As Insider Purchases Lose Another US$65kDecember 17, 2024 | finance.yahoo.comCharles Schwab Investment Management Inc. Acquires 126,110 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)Charles Schwab Investment Management Inc. lifted its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 28.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 572,December 16, 2024 | marketbeat.comXTX Topco Ltd Makes New $500,000 Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)XTX Topco Ltd acquired a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 103,348 shares of the company's stock, valued at approximately $500,00December 14, 2024 | marketbeat.comPCSK9 Inhibitors Treatment Market 2034: Clinical Trials, Medication, Pipeline Therapies, EMA, PDMA, FDA Approvals and Companies by DelveInsightDecember 11, 2024 | theglobeandmail.comStifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)December 11, 2024 | markets.businessinsider.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. boosted its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 72.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,559,393 shares of the company's stock afDecember 6, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Redmile Group LLCRedmile Group LLC trimmed its stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 5.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,383,366 shares of the company's stock after selling 80,040 shares duringDecember 5, 2024 | marketbeat.comVerve Therapeutics: Cutting-Edge Science But Highly Risky StockDecember 4, 2024 | seekingalpha.comPDT Partners LLC Sells 152,061 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)PDT Partners LLC decreased its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 45.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 181,803 shares of the company's stock afterDecember 3, 2024 | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 29, 2024 | globenewswire.comBraidwell LP Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Braidwell LP purchased a new position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 623,980 shares of the company's stock, valued at approximately $3,020,000. Braidwell LNovember 29, 2024 | marketbeat.comAlgert Global LLC Increases Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)Algert Global LLC lifted its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 63.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 224,216 shares of the company's stock after buying an additNovember 29, 2024 | marketbeat.comAcuta Capital Partners LLC Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Acuta Capital Partners LLC acquired a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 146,100 shares of the company's stock, vNovember 28, 2024 | marketbeat.comGSA Capital Partners LLP Reduces Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)GSA Capital Partners LLP cut its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 82.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 36,102 shares of the company's stock after selling 167,575 shares during theNovember 25, 2024 | marketbeat.comVERV FY2024 EPS Estimate Boosted by Cantor FitzgeraldVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Verve Therapeutics in a note issued to investors on Monday, November 11th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will post earnings perNovember 14, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for VERV FY2024 Earnings?Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings estimates for Verve Therapeutics in a research note issued to investors on Wednesday, November 6th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings ofNovember 8, 2024 | marketbeat.comResearch Analysts Offer Predictions for VERV FY2024 EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Research analysts at Lifesci Capital lifted their FY2024 earnings estimates for shares of Verve Therapeutics in a research report issued on Tuesday, November 5th. Lifesci Capital analyst C. Jubinville now anticipates that the company will posNovember 8, 2024 | marketbeat.comFY2024 Earnings Estimate for VERV Issued By William BlairVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Investment analysts at William Blair upped their FY2024 earnings per share estimates for shares of Verve Therapeutics in a report issued on Tuesday, November 5th. William Blair analyst M. Minter now forecasts that the company will post earninNovember 8, 2024 | marketbeat.comVerve Therapeutics price target lowered to $17 from $20 at RBC CapitalNovember 6, 2024 | markets.businessinsider.comVerve Therapeutics Reports Q3 Progress and FinancialsNovember 6, 2024 | markets.businessinsider.comPositive Outlook on Verve Therapeutics: Promising VERVE-102 Trial Results and Genetic Editing AdvancementsNovember 6, 2024 | markets.businessinsider.comHC Wainwright Has Lowered Expectations for Verve Therapeutics (NASDAQ:VERV) Stock PriceHC Wainwright lowered their price objective on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday.November 6, 2024 | marketbeat.comVerve Therapeutics Positioned for Growth with Promising Clinical Progress and Strategic ExpansionNovember 6, 2024 | markets.businessinsider.comVerve Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 6, 2024 | finance.yahoo.comVerve Therapeutics (NASDAQ:VERV) Trading Up 10.1% - Here's What HappenedVerve Therapeutics (NASDAQ:VERV) Trading Up 10.1% - Still a Buy?November 5, 2024 | marketbeat.comVerve Therapeutics sees cash runway through 2026November 5, 2024 | markets.businessinsider.comVerve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial ResultsNovember 5, 2024 | finance.yahoo.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsOctober 29, 2024 | markets.businessinsider.comFINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action LawsuitOctober 28, 2024 | markets.businessinsider.comVERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law FirmOctober 28, 2024 | prnewswire.comVerve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERVOctober 28, 2024 | prnewswire.comVerve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERVOctober 28, 2024 | prnewswire.comVERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERVOctober 27, 2024 | globenewswire.com Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Media Mentions By Week VERV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼0.340.41▲Average Medical News Sentiment VERV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼66▲VERV Articles Average Week Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Apogee Therapeutics News Today Amphastar Pharmaceuticals News Today Iovance Biotherapeutics News Today Tarsus Pharmaceuticals News Today ImmunityBio News Today Disc Medicine News Today Belite Bio News Today Wave Life Sciences News Today Arcutis Biotherapeutics News Today Galapagos News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
